Answer a short survey to help the ACR’s Committee on Rheumatologic Care decide whether the ACR should seek CMS approval for synovial fluid crystal analysis as a provider-performed microscopy procedure.
Flares Rare After COVID Vaccination
The development of a vaccine for COVID-19 changed the course of the pandemic; however, it also raised questions about whether to withhold or reduce immunosuppressive therapies and other medications for patients with inflammatory, rheumatic and musculoskeletal disease (IRMD), note the authors of a new study published in Annals of the Rheumatic Diseases. An argument for…
ACR Image Competition 2024 Results, Part 4
For the 2024 Image Competition, the ACR sought images with educational or remarkable manifestations representing a diverse range of pediatric patients with autoimmune, inflammatory, infectious and malignant drivers of rheumatic disease. Here, we showcase the winning images from the Middle East and North Africa. Lipoma Arborescens Revealed A 10-year-old boy, presented with a five-year history…
Cannabis for Pain Management in Rheumatology
‘Cannabis has a long history of being used for pain management,’ says Physician Editor Bharat Kumar, MD, MME, FACP, FAAAAI, RhMSUS. ‘What does it mean for rheumatology patients moving forward? Read our article for one answer to this question.’ As cannabis becomes more widely legalized, both in the U.S. and internationally, its use for pain…
Experts Discuss Guidelines for Interstitial Lung Disease in Systemic Autoimmune Rheumatic Disease
Over 50% of patients with systemic sclerosis (SSc) develop interstitial lung disease (ILD), and rheumatologists have long recognized this major cause of morbidity and mortality.1 Sindhu R. Johnson, MD, PhD, professor of medicine at the University of Toronto, Canada, and director of the Toronto Scleroderma Program, notes that more recent studies have increased our awareness…
Precision Medicine Study Examines Blood-Based Immunophenotyping in Patients with RA
For patients with rheumatoid arthritis (RA), analyzing immune cell diversity in peripheral blood revealed five major immunotype groups, each exhibiting a different response to various biologic or targeted synthetic disease-modifying anti-rheumatic drugs (DMARDs). This is according to a 2024 study published in Annals of the Rheumatic Disease that aimed to stratify the patients based on…
AI’s Expanding Role in Rheumatology & Healthcare
Disease detection, access to care and remote patient monitoring are just a few areas in which AI is expected to aid rheumatology, but there will still be room for the human touch.
In the Details: Diagnosing PsA Requires Drilling Down
Rheumatologists must do some detective work into a patient’s signs and symptoms when considering a psoriatic arthritis diagnosis, according to Philip J. Mease, MD, MACR
Metabolic Syndrome & RA Treatment Response
Research from Baker et al. demonstrated a strong association between the presence of metabolic syndrome and lower response rates to advanced therapies in patients with RA.
Deucravacitinib Promising for PsA
Results from two studies found that deucravacitinib improved the signs and symptoms of patients with psoriatic arthritis who were biologic disease-modifying anti-rheumatic drug naive and those previously treated with a tumor necrosis factor α inhibitor.
- « Previous Page
- 1
- …
- 10
- 11
- 12
- 13
- 14
- …
- 348
- Next Page »